InBrace

Key People

• John Pham - Co-Founder and CEO
• Hongsheng Tong - Co-Founder, CIO, CMO, and Principal Orthodontic Scientist
• Jeffrey Nardoci - President and COO
• Kevin Cousins - CFO
• Clint Carnell - CEO
• Greg Del Fium - Chief Financial Officer
• Jessica Solomon - Chief People Officer
• Mark Price - SVP of Product Performance
• Dr. Tera Poole - Director of Clinical Affairs
• Michael Schultz - VP of Sales

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and business management.

The presence of multiple successful MedTech entrepreneurs in the leadership team suggests a strong foundation for strategic decision-making and innovation.

Clinical Need

Aspect: Strong
Summary: InBrace addressed a significant clinical need for discreet orthodontic solutions.

The demand for less visible orthodontic treatments is substantial, and InBrace's behind-the-teeth solution catered to this need effectively.

Competition

Aspect: Very crowded + Strategics
Summary: The orthodontic market is highly competitive, with major players like Invisalign dominating.

InBrace faced intense competition from established companies with significant market share and resources, making market penetration challenging.

Technical Challenge

Aspect: Complex
Summary: The technology behind InBrace's Smartwire system was complex and required specialized training.

The complexity of the system may have hindered widespread adoption among orthodontists, as it necessitated new workflows and training.

Patent

Aspect: Very Strong
Summary: InBrace held a robust patent portfolio for its innovative orthodontic solutions.

A strong patent portfolio provided InBrace with a competitive edge and protected its unique technology from imitation.

Financing

Aspect: Well-funded
Summary: InBrace secured significant funding, including a $102 million Series D round.

Despite substantial funding, InBrace faced financial challenges leading to its shutdown, indicating potential issues in financial management or market adoption.

Regulatory

Aspect: 510k/PMA
Summary: InBrace's products were FDA registered, indicating compliance with regulatory standards.

While regulatory approval was achieved, it did not translate into sustained market success, possibly due to other operational challenges.

Opportunity Rollup

Odds of Success

3.2

Peak Market Share

3.9

Segment CAGR

<em>Unknown</em>

Market Segment

Orthodontic Devices

Market Sub Segment

Lingual Braces

Key Takeaway

InBrace's innovative approach to discreet orthodontic treatment faced significant market and operational challenges, leading to its closure despite substantial funding and a strong patent portfolio.